recent publications
-
academic article
- Yue, E. W., Sparks, R., Polam, P., Modi, D., Douty, B., Wayland, B., Glass, B., Takvorian, A., Glenn, J., Zhu, W., Bower, M., Liu, X., et al. INCB24360 (epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (ID01) inhibitor for immunooncology ACS Medicinal Chemistry Letters 2017 8:486-491 DOI:10.1021/acsmedchemlett.6b00391 PMID:28523098 PMCID:PMC5430407
- Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., Waeltz, P., Bowman, K. J., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 2010 115:3520-3530 DOI:10.1182/blood-2009-09-246124 PMID:20197554
- Hu, Z., Jiang, X., Albright, C. F., Graciani, N., Yue, E., Zhang, M., Zhang, S. Y., Bruckner, R., Diamond, M., Dowling, R., Rafalski, M., Yeleswaram, S., et al. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents Bioorganic & Medicinal Chemistry Letters 2010 20:853-856 DOI:10.1016/j.bmcl.2009.12.084 PMID:20060717
- Koblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., Combs, A. P., Scherle, P. A., et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors Molecular Cancer Therapeutics 2010 9:489-498 DOI:10.1158/1535-7163.mct-09-0628 PMID:20124451
- Yue, E. W., Douty, B., Wayland, B., Bower, M., Liu, X., Leffet, L., Wang, Q., Bowman, K. J., Hansbury, M. J., Liu, C., Wei, M., Li, Y., et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model Journal of Medicinal Chemistry 2009 52:7364-7367 DOI:10.1021/jm900518f PMID:19507862
- Hartz, R. A., Ahuja, V. T., Arvanitis, A. G., Rafalski, M., Yue, E. W., Denhart, D. J., Schmitz, W. D., Ditta, J. L., Deskus, J. A., Brenner, A. B., Hobbs, F. W., Payne, J., et al. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists Journal of Medicinal Chemistry 2009 52:4173-4191 DOI:10.1021/jm900301y PMID:19552437
- Hartz, R. A., Ahuja, V. T., Rafalski, M., Schmitz, W. D., Brenner, A. B., Denhart, D. J., Ditta, J. L., Deskus, J. A., Yue, E. W., Arvanitis, A. G., Lelas, S., Li, Y. W., et al. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists Journal of Medicinal Chemistry 2009 52:4161-4172 DOI:10.1021/jm900302q PMID:19552436
- Douty, B., Wayland, B., Ala, P. J., Bower, M. J., Pruitt, J., Bostrom, L., Wei, M., Klabe, R., Gonneville, L., Wynn, R., Burn, T. C., Liu, P. C. C., et al. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines Bioorganic & Medicinal Chemistry Letters 2008 18:66-71 DOI:10.1016/j.bmcl.2007.11.012 PMID:18037290
- Ala, P. J., Gonneville, L., Hillman, M., Becker-Pasha, M., Yue, E. W., Douty, B., Wayland, B., Polam, P., Crawley, M. L., McLaughlin, E., Sparks, R. B., Glass, B., et al. Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B Journal of Biological Chemistry 2006 281:38013-38021 DOI:10.1074/jbc.M607913200 PMID:17028182
- Ala, P. J., Gonneville, L., Hillman, M. C., Becker-Pasha, M., Wei, M., Reid, B. G., Klabe, R., Yue, E. W., Wayland, B., Douty, B., Polam, P., Wasserman, Z., et al. Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics Journal of Biological Chemistry 2006 281:32784-32795 DOI:10.1074/jbc.M606873200 PMID:16916797
- Yue, E. W., Wayland, B., Douty, B., Crawley, M. L., McLaughlin, E., Takvorian, A., Wasserman, Z., Bower, M. J., Wei, M., Li, Y., Ala, P. J., Gonneville, L., et al. Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure-activity relationships of a peptide scaffold Bioorganic & Medicinal Chemistry 2006 14:5833-5849 DOI:10.1016/j.bmc.2006.05.032 PMID:16769216
- Combs, A. P., Zhu, W., Crawley, M. L., Glass, B., Polam, P., Sparks, R. B., Modi, D., Takvorian, A., McLaughlin, E., Yue, E. W., Wasserman, Z., Bower, M., et al. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic Journal of Medicinal Chemistry 2006 49:3774-3789 DOI:10.1021/jm0600904 PMID:16789735
- Combs, A. P., Yue, E. W., Bower, M., Ala, P. J., Wayland, B., Douty, B., Takvorian, A., Polam, P., Wasserman, Z., Zhu, W., Crawley, M. L., Pruitt, J., et al. Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics Journal of Medicinal Chemistry 2005 48:6544-6548 DOI:10.1021/jm.0504555 PMID:16220970
- Albright, C. F., Graciani, N., Han, W., Yue, E., Stein, R., Lai, Z., Diamond, M., Dowling, R., Grimminger, L., Zhang, S. Y., Behrens, D., Musselman, A., et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity Molecular Cancer Therapeutics 2005 4:751-760 DOI:10.1158/1535-7163.mct-05-0006 PMID:15897239
- Yue, E. W., DiMeo, S. V., Higley, C. A., Markwalder, J. A., Burton, C. R., Benfield, P. A., Grafstrom, R. H., Cox, S., Muckelbauer, J. K., Smallwood, A. M., Chen, H., Chang, C. H., et al. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3 Bioorganic & Medicinal Chemistry Letters 2004 14:343-346 DOI:10.1016/j.bmcl.2003.11.008 PMID:14698155
- Yue, E. W., Higley, C. A., DiMeo, S. V., Carini, D. J., Nugiel, D. A., Benware, C., Benfield, P. A., Burton, C. R., Cox, S., Grafstrom, R. H., Sharp, D. M., Sisk, L. M., et al. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3 Journal of Medicinal Chemistry 2002 45:5233-5248 DOI:10.1021/jm0201722 PMID:12431051
-
Nicolaou, K. C.*, Yue, E. W.*
Total synthesis of selected natural products
Pure and Applied Chemistry
1997
69:413-418
DOI:10.1351/pac199769030413
(* = equal contribution)
-
Nicolaou, K. C., Postema, M. H. D., Yue, E. W., Nadin, A.
An olefin metathesis based strategy for the construction of the JKL, OPQ, and UVW ring systems of maitotoxin
Journal of the American Chemical Society
1996
118:10335-10336
DOI:10.1021/ja962862z
-
Nicolaou, K. C.*, Yue, E. W.*, Lagreca, S., Nadin, A., Yang, Z., Leresche, J. E., Tsuri, T., Naniwa, Y., Dericcardis, F.
Synthesis of zaragozic acid A/squalestatin S1
Chemistry-a European Journal
1995
1:467-494
DOI:10.1002/chem.19950010712
(* = equal contribution)
-
Nicolaou, K. C., Nadin, A., Leresche, J. E., Lagreca, S., Tsuri, T., Yue, E. W., Yang, Z.
Synthesis of the first fully functionalized core of the zaragozic acids squalestatins
Angewandte Chemie-International Edition
1994
33:2187-2190
DOI:10.1002/anie.199421871
-
Nicolaou, K. C., Nadin, A., Leresche, J. E., Yue, E. W., Lagreca, S.
Total synthesis of zaragozic-acid-A squalestatin-S1
Angewandte Chemie-International Edition
1994
33:2190-2191
DOI:10.1002/anie.199421901
-
Nicolaou, K. C.*, Yue, E. W.*, Naniwa, Y., Dericcardis, F., Nadin, A., Leresche, J. E., Lagreca, S., Yang, Z.
Zaragozic-acid-A squalestatin-S1 - synthetic and retrosynthetic studies
Angewandte Chemie-International Edition
1994
33:2184-2187
DOI:10.1002/anie.199421841
(* = equal contribution)
-
Nicolaou, K. C., Smith, A. L., Yue, E. W.
Chemistry and biology of natural and designed enediynes
Proceedings of the National Academy of Sciences of the United States of America
1993
90:5881-5888
DOI:10.1073/pnas.90.13.5881
PMID:8327459
- Yue, E. W., Gerdes, J. M., Mathis, C. A. Synthesis of 2,3-dimethoxy-5-iodobenzoic acid Journal of Organic Chemistry 1991 56:5451-5456 DOI:10.1021/jo00018a048
-
chapter
- Nicolaou, K. C., Yue, E. W., Oshima, T. New roads to molecular complexity The New Chemistry. 168-198. 2000